Venture Capital Investors

5AM Ventures

venture capital fund 5AM Ventures invests in innovative tech ventures.

Venture Investor Overview

Venture Investor
5AM Ventures
Status
Active
Investor Type
Venture Capital
Activity Level
185 transactions
Funds Raised
At least $1.5 billion
Industry Focus
Biopharmaceutical
Healthcare IT
Medical Devices & Instruments

Contact Information

Contact
John Diekman
Title
Founder & Managing Partner
Mailing Address
501 Second St. 350
San Francisco, CA 94107
USA
Phone
415-993-8570
Website
www.5amventures.com
Email Address
Not Recorded

Background Information

Overview
5AM Ventures is a leading venture capital firm focused on building next-generation life science companies capable of delivering outstanding returns to our investors. We support companies solving important healthcare needs via cutting-edge breakthroughs in medicine and science. Our portfolio companies spearhead novel approaches to diagnose, prevent and treat a wide range of medical conditions.
Profile
5AM Ventures LinkedIn Company Profile
Social Media
5AM Ventures Company Twitter Account
Company News
5AM Ventures News
Facebook
5AM Ventures on Facebook
YouTube
5AM Ventures on YouTube
Last Transaction
2/14/2024

Transaction History

Our records indicate that 5AM Ventures invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
Latigo Biotherapeutics
2/14/2024
$135,000,000
Tyra Biosciences
2/2/2024
$200,000,000
Radionetics Oncology
1/3/2024
$52,500,000
Nouscom
11/14/2023
$73,693,000
MapLight Therapeutics
10/30/2023
$225,000,000
Precede Biosciences
10/10/2023
$57,000,000
Carmot Therapeutics
5/25/2023
$150,000,000
Ensoma
1/10/2023
$85,000,000
Escient Pharmaceuticals
11/28/2022
$120,000,000
Novome Biotechnologies
9/13/2022
$43,500,000
CAMP4 Therapeutics
7/20/2022
$100,000,000
Magnetic Insight
6/23/2022
$17,000,000
Dianthus Therapeutic
5/3/2022
$100,000,000
Expansion Therapeutics
9/30/2021
$80,000,000
RareCyte
9/13/2021
$24,000,000
Disc Medicine
9/2/2021
Unknown
Neurogastrx
8/27/2021
$60,000,000
TMRW Life Sciences
7/21/2021
$105,000,000
CAMP4 Therapeutics
6/16/2021
$45,000,000
Entrada Therapeutics
4/1/2021
$116,000,000
Artiva Biotherapeutics
3/2/2021
$120,000,000
Ensoma
2/12/2021
$70,000,000
Pear Therapeutics
12/9/2020
$80,000,000
Kinaset Therapeutics
12/1/2020
$40,000,000
Inipharm
11/12/2020
$35,000,000
Escient Pharmaceuticals
9/15/2020
$77,500,000
Vor Biopharma
7/8/2020
$110,000,000
Artiva Biotherapeutics
6/26/2020
$78,000,000
Rallybio
5/20/2020
$145,000,000
Akouos
3/4/2020
$105,000,000
Novome Biotechnologies
1/8/2020
$33,000,000
RareCyte
12/24/2019
$22,000,000
TMRW Life Sciences
12/18/2019
$25,000,000
Cleave Therapeutics
8/8/2019
$12,000,000
Purigen Biosystems
6/13/2019
$26,400,000
CinCor Pharma
5/15/2019
$50,000,000
Vor Biopharma
2/15/2019
$42,000,000
Kinestral Technologies
1/31/2019
$100,000,000
Pear Therapeutics
1/7/2019
$64,000,000
Cabaletta Bio
1/4/2019
$50,000,000
Entrada Therapeutics
12/19/2018
$59,000,000
Magnetic Insight
12/13/2018
$18,000,000
Impel NeuroPharma
12/7/2018
$67,500,000
Aprea Therapeutics
12/3/2018
$56,869,550
Biodesy
9/11/2018
$20,000,000
Akouos
8/8/2018
$50,000,000
Nohla Therapeutics
5/16/2018
$45,000,000
Escient Pharmaceuticals
5/10/2018
$40,000,000
Rallybio
4/26/2018
$37,000,000
Arvinas
4/5/2018
$55,000,000
IDEAYA Biosciences
3/16/2018
$94,000,000
Crinetics Pharmaceuticals
3/15/2018
$63,500,000
Neurogastrx
1/5/2018
$45,000,000
Expansion Therapeutics
1/4/2018
$55,300,000
Pear Therapeutics
1/3/2018
$50,000,000
Akouos
12/1/2017
$7,500,000
RareCyte
8/11/2017
$30,000,000
Homology Medicines
8/2/2017
$83,500,000
Scientist.com
5/16/2017
$24,000,000
Kinestral Technologies
2/1/2017
$65,000,000
scPharmaceuticals
1/5/2017
$45,600,000
Impel NeuroPharma
12/6/2016
$36,000,000
Nohla Therapeutics
12/1/2016
$43,500,000
Chrono Therapeutics
9/9/2016
$47,600,000
Cleave Biosciences
8/9/2016
$37,000,000
Purigen Biosystems
5/18/2016
$18,200,000
IDEAYA Biosciences
5/5/2016
$46,000,000
Homology Medicines
5/3/2016
$43,500,000
Bird Rock Bio
3/31/2016
$5,000,000
Pear Therapeutics
2/3/2016
$20,000,000
Biodesy
1/25/2016
$10,000,000
Millendo Therapeutics
1/4/2016
$62,000,000
Crinetics Pharmaceuticals
11/3/2015
$40,000,000
Arvinas
10/21/2015
$41,600,000
Portal Instruments
10/20/2015
$25,000,000
Audentes Therapeutics
10/14/2015
$65,000,000
Chrono Therapeutics
9/30/2015
$17,691,000
Precision NanoSystems
9/30/2015
$13,400,000
Igenica
9/30/2015
$2,250,000
Millendo Therapeutics
6/30/2015
$322,000
scPharmaceuticals
6/30/2015
$9,566,000
RuiYi
6/30/2015
$5,000,000
Kinestral Technologies
6/30/2015
$5,937,000
Spyryx Biosciences
5/8/2015
$18,000,000
Pear Therapeutics
3/20/2015
Unknown
RuiYi
12/31/2014
$5,000,000
Arvinas
12/31/2014
$6,608,000
Cellular Research
12/31/2014
$200,000
Audentes Therapeutics
12/3/2014
$42,500,000
Pear Therapeutics
9/30/2014
$1,250,000
Igenica
9/30/2014
$7,033,000
Cleave Biosciences
9/30/2014
$27,000,000
Millendo Therapeutics
6/30/2014
$6,450,000
Pearl Therapeutics
6/30/2014
$500,000
Cidara Therapeutics
6/30/2014
$32,000,000
Chrono Therapeutics
6/13/2014
$32,000,000
Ceterix Orthopaedics
5/13/2014
$18,000,000
EPIRUS Biopharmaceuticals
4/17/2014
$36,000,000
Arvinas
3/31/2014
$5,100,000
Ambrx
3/31/2014
$105,000
Cidara Therapeutics
3/31/2014
$500,000
scPharmaceuticals
3/27/2014
$16,000,000
RuiYi
3/27/2014
$15,000,000
Igenica
1/28/2014
$14,000,000
Cellular Research
12/31/2013
$1,300,000
Achaogen
12/31/2013
$10,000,000
Biodesy
10/18/2013
$15,000,000
EPIRUS Biopharmaceuticals
9/30/2013
$2,500,000
Cidara Therapeutics
9/30/2013
$500,000
Arvinas
9/27/2013
$19,250,000
Audentes Therapeutics
7/19/2013
$30,000,000
Igenica
6/30/2013
$13,030,100
Pearl Therapeutics
3/31/2013
$41,726,900
Millendo Therapeutics
3/31/2013
$5,017,000
Ceterix Orthopaedics
1/22/2013
$19,500,000
Igenica
12/31/2012
$10,250,000
Flexion Therapeutics
12/4/2012
$20,000,000
Pearl Therapeutics
11/13/2012
$65,000,000
Novira Therapeutics
8/23/2012
$23,000,000
Millendo Therapeutics
8/6/2012
$16,000,000
Viveve Medical
6/30/2012
$7,210,000
EPIRUS Biopharmaceuticals
6/30/2012
$8,083,000
Igenica
6/12/2012
$33,000,000
Rennovia
12/31/2011
$22,333,000
Cleave Biosciences
10/11/2011
$42,000,000
Incline Therapeutics
9/30/2011
$21,500,000
Pulmatrix
8/15/2011
$14,000,000
DVS Sciences
7/14/2011
$14,600,000
EPIRUS Biopharmaceuticals
3/31/2011
$8,036,000
Achaogen
12/31/2010
$20,952,300
Semprus BioSciences
12/13/2010
$18,000,000
Pearl Therapeutics
10/19/2010
$69,000,000
Relypsa
9/13/2010
$70,000,000
Rennovia
6/30/2010
$6,000,000
WaveRx
6/30/2010
$503,000
Incline Therapeutics
6/22/2010
$43,000,000
Igenica
6/11/2010
$24,000,000
Viveve Medical
4/29/2010
$4,000,000
Achaogen
4/7/2010
$56,000,000
Phenomix
3/31/2010
$5,955,800
Pearl Therapeutics
2/1/2010
$15,000,000
Pulmatrix
11/2/2009
$30,200,000
Flexion Therapeutics
10/16/2009
$33,000,000
Rennovia
9/18/2009
$6,000,000
TiVaMed
4/27/2009
$6,000,000
Ambrx
4/1/2009
$10,000,000
Relypsa
3/11/2009
$10,000,000
RuiYi
1/8/2009
$25,000,000
Igenica
12/31/2008
$3,099,900
KaloBios Pharmaceuticals
12/22/2008
$12,000,000
Semprus BioSciences
12/14/2008
$8,000,000
Pulmatrix
9/30/2008
$4,000,000
Pearl Therapeutics
7/3/2008
$18,000,000
RuiYi
4/15/2008
$8,000,000
Antipodean Pharmaceuticals
12/31/2007
$2,980,000
TiVaMed
12/31/2007
$4,502,000
Synosia Therapeutics
12/31/2007
$10,000,000
Relypsa
10/29/2007
$33,000,000
Pearl Therapeutics
9/6/2007
$15,500,000
KaloBios Pharmaceuticals
7/23/2007
$20,000,000
Andrien Smith
6/30/2007
$15,000,000
Pulmatrix
6/30/2007
$8,000,000
Marcadia Biotech
5/15/2007
$15,000,000
Variation Biotechnologies
1/5/2007
$37,500,000
Synosia Therapeutics
1/5/2007
$32,500,000
Pulmatrix
12/31/2006
$650,000
Achaogen
10/10/2006
$26,000,000
Ambrx
7/5/2006
$52,000,000
Synosia Therapeutics
6/30/2006
$30,000,100
Ambrx
6/30/2006
$28,364,000
Ilypsa
3/31/2006
$16,000,000
Synosia Therapeutics
3/31/2006
$2,499,900
Ambrx
3/31/2006
$5,000,000
Pulmatrix
3/31/2006
$2,675,000
Antipodean Pharmaceuticals
9/30/2005
$14,550,000
Ilypsa
7/19/2005
$36,000,000
Miikana
6/30/2005
$1,000,000
Ikaria
6/30/2005
$2,500,000
WaveRx
6/30/2005
$3,000,100
Ambrx
4/8/2005
$23,400,000
KaloBios Pharmaceuticals
3/16/2005
$20,000,000
Alexza Pharmaceuticals
1/6/2005
$52,000,000
Panomics
9/14/2004
$16,400,000
Kalypsys
8/4/2004
$29,000,000
Ambrx
9/22/2003
$12,500,000

 

Investor Contacts

Title
Name
Email & Social
Partner
David Allison
  David Allison LinkedIn Profile  David Allison Twitter Account  David Allison News  David Allison on Facebook
Partner
Brian Daniels
  Brian Daniels LinkedIn Profile  Brian Daniels Twitter Account  Brian Daniels News  Brian Daniels on Facebook
Managing Partner
John Diekman
  John Diekman LinkedIn Profile  John Diekman Twitter Account  John Diekman News  John Diekman on Facebook
Managing Partner
Kush Parmar
  Kush Parmar LinkedIn Profile  Kush Parmar Twitter Account  Kush Parmar News  Kush Parmar on Facebook
Managing Partner
Scott Rocklage
  Scott Rocklage LinkedIn Profile  Scott Rocklage Twitter Account  Scott Rocklage News  Scott Rocklage on Facebook
Managing Partner
Andrew Schwab
  Andrew Schwab LinkedIn Profile  Andrew Schwab Twitter Account  Andrew Schwab News  Andrew Schwab on Facebook

 

Funds

Our database includes the following fund closing(s) for 5AM Ventures. If we are missing funds, please contact us.

Fund Description
Vintage Date
Fund Amount
5AM Opportunities I
2/13/2019
$147,000,000
5AM Ventures VI
2/13/2019
$350,000,000
5AM Ventures V
5/27/2016
$285,000,000
5AM Ventures IV
12/3/2013
$250,000,000
5AM Ventures III
12/7/2009
$220,000,000
5AM Ventures II
12/19/2006
$150,000,000
5AM Ventures I
9/30/2003
$65,000,000

 

Portfolio Companies

5AM Ventures has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
Achaogen
Akouos
Alexza Pharmaceuticals
Ambrx
Andrien Smith
Antipodean Pharmaceuticals
Aprea Therapeutics
Artiva Biotherapeutics
Arvinas
Audentes Therapeutics
Biodesy
Bird Rock Bio
Cabaletta Bio
CAMP4 Therapeutics
Carmot Therapeutics
Cellular Research
Ceterix Orthopaedics
Chrono Therapeutics
Cidara Therapeutics
CinCor Pharma
Cleave Biosciences
Cleave Therapeutics
Crinetics Pharmaceuticals
Dianthus Therapeutic
Disc Medicine
DVS Sciences
Ensoma
Entrada Therapeutics
EPIRUS Biopharmaceuticals
Escient Pharmaceuticals
Expansion Therapeutics
Flexion Therapeutics
Homology Medicines
IDEAYA Biosciences
Igenica
Ikaria
Ilypsa
Impel NeuroPharma
Incline Therapeutics
Inipharm
KaloBios Pharmaceuticals
Kalypsys
Kinaset Therapeutics
Kinestral Technologies
Latigo Biotherapeutics
Magnetic Insight
MapLight Therapeutics
Marcadia Biotech
Miikana
Millendo Therapeutics
Neurogastrx
Nohla Therapeutics
Nouscom
Novira Therapeutics
Novome Biotechnologies
Panomics
Pear Therapeutics
Pearl Therapeutics
Phenomix
Portal Instruments
Precede Biosciences
Precision NanoSystems
Pulmatrix
Purigen Biosystems
Radionetics Oncology
Rallybio
RareCyte
Relypsa
Rennovia
RuiYi
Scientist.com
scPharmaceuticals
Semprus BioSciences
Spyryx Biosciences
Synosia Therapeutics
TiVaMed
TMRW Life Sciences
Tyra Biosciences
Variation Biotechnologies
Viveve Medical
Vor Biopharma
WaveRx

 

 

 

 

Browse more venture capital investors:

574 Invest | 5G Open Innovation Lab

 

Share this article

 

About Our Venture Capital Investor Database

Our data comes from VentureDeal.com, a leading provider of venture capital transaction data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.